Defective Pharmaceutical Claims in Ireland: A Plain-English Guide for Injured Patients

What counts as a defective pharmaceutical?

A medicine is defective in Irish law when it does not provide the safety a person is entitled to expect, taking all the circumstances into account. That test comes from section 5 of the 1991 Act [1] and looks at the way the product is presented, the use to which it could reasonably be put, and the time it was placed on the market.

Lawyers and regulators usually group defects into four practical categories. Manufacturing defects occur when a specific batch deviates from the approved specification, for example contamination of a sterile injectable or particle-size errors that triggered the 2025 Palmeux suspension recall. Design defects occur when the molecule itself, when used as intended, carries an unreasonable risk profile. Inadequate-warning defects occur when the patient leaflet, the Summary of Product Characteristics, or a Direct Healthcare Professional Communication failed to disclose a material risk. Marketing defects occur when off-label promotion or misleading advertising drove inappropriate use.

The HPRA classifies confirmed quality defects as Class I (life-threatening), Class II (could cause illness or mistreatment), or Class III (low risk to health). It then runs recalls at wholesale, pharmacy, or patient level [4]. In 2025 the HPRA detained 763,027 dosage units of falsified or illegal medicines, with a sharp rise in counterfeit GLP-1 weight-loss drugs bought online. Counterfeit products bought outside the regulated supply chain almost never lead to a viable claim because the "producer" cannot be identified.

The hybrid distinction at the heart of pharmaceutical injury claims

In short: A hybrid pharmaceutical claim combines strict liability against the manufacturer under the Liability for Defective Products Act 1991 with clinical negligence against the prescriber, dispenser, or hospital. Most successful Irish pharmaceutical injury cases run on this hybrid basis. The proprietary Hybrid Claim Test sets out the four diagnostic questions that determine viability.

In Ireland, the most valuable pharmaceutical claims are hybrid. A defective drug meets a negligent prescribing or dispensing decision in the same patient. Both Pandemrix and sodium valproate were litigated on this basis. The drug had a profile of risk. The State, the HSE, or the prescriber failed to communicate it.

We call this the Hybrid Claim Test. Apply it to your facts in four steps. (1) Was there a defect, an unwarned risk, or a quality failure in the medicine itself? (2) Was there a separate failure by the prescriber, dispenser, or hospital, wrong drug, wrong dose, wrong patient, missed monitoring, or absent warning? (3) Did both failures contribute materially to the same injury? (4) Are both routes within their respective limitation periods? If you answer yes to all four, the Hybrid Claim Test is satisfied. The case runs as a hybrid action with two defendants and two pressure points.

The Hybrid Claim Test matters because it changes three things at once. First, the evidence bundle expands beyond the manufacturer's documents to include the patient's clinical record, the consenting discussion, and the prescribing rationale. Second, two defendants come into play, often with separate insurers and separate appetites to settle. Third, two limitation clocks run in parallel, which can save a case where one is missed.

The hybrid frame also matters for procedural reasons. A pure product-liability claim under the 1991 Act may need authorisation from the Injuries Resolution Board before proceedings can issue. A claim framed as medical negligence is exempt under section 3(d) of the Personal Injuries Assessment Board Act 2003 [5]. A hybrid claim usually proceeds directly to the High Court because the negligence element controls the procedural route.

Strict liability vs medical negligence: same harm, two routes

The two routes look similar in outcome but turn on very different legal tests.

Strict liability sounds like the easier route because you don't need to prove negligence. The reality is harder. The Dunne test, while fault-based, lets you compel disclosure of the prescriber's records and the hospital's protocols. The 1991 Act's strict-liability advantage is often offset by the development-risk defence (covered below). Most experienced solicitors run both claims in parallel where the facts allow.

Time limits: the 3-year and 2-year clocks running in parallel

In short: Two clocks run in parallel for hybrid pharmaceutical claims in Ireland. The 1991 Act gives 3 years from date of knowledge under section 7(1), with an absolute 10-year long stop under section 7(2). The clinical negligence route gives 2 years from date of knowledge under section 3 of the Statute of Limitations (Amendment) Act 1991. The 3-year extension proposed under section 221 of the Legal Services Regulation Act 2015 has never been commenced.

A common misunderstanding is worth flagging. Some sources state that defective product claims have a "2-year minus one day" limitation. That confuses the standard personal-injury clock with the 1991 Act clock. The 1991 Act gives three years, not two.

The 3-year clock. Under section 7(1) of the 1991 Act [1], a claim against the producer cannot be brought after three years from the date the cause of action accrued or, if later, the date of knowledge. Date of knowledge means the date you became aware (or should reasonably have become aware) of the damage, the defect, and the identity of the producer.

The 10-year long stop. Under section 7(2), the right of action is extinguished entirely 10 years after the producer first put the product into circulation, regardless of when the injury appeared. This is absolute. It overrides the usual extensions for minors and people who lacked capacity. A drug taken 12 years ago is normally outside the 1991 Act, even if the injury only became apparent last month.

A detail that catches many claimants off guard: the 10-year long stop runs from the date the producer first placed the specific batch into circulation, not from the date you took it. If the medicine sat in distribution for 14 months before reaching your pharmacy, that 14 months has already eaten into your 10-year window. This is the single most common reason a valproate or older-vaccine case becomes untenable on the product-liability route while remaining live on the negligence route. Date-of-circulation evidence comes from the manufacturer's batch records, secured early in pre-action correspondence.

The 2-year clinical-negligence clock. A negligence claim against a prescriber or pharmacist runs under section 3 of the Statute of Limitations (Amendment) Act 1991 (as amended by section 7 of the Civil Liability and Courts Act 2004) [3] for two years from the date of knowledge as defined in section 2 of that Act. The proposed three-year extension under section 221 of the Legal Services Regulation Act 2015 has never been commenced and remains inactive as of May 2026, so the limit today is strictly two years. Medical negligence time limits are tighter than the product-liability ones.

Why this matters in hybrid cases. We call this the Parallel-Clock Test. Run it on every set of facts. The Parallel-Clock Test works in three steps. (1) Identify the date of knowledge for each route separately, the day you (or a reasonable patient in your shoes) first connected the injury to the medicine for the product-liability route, and the day you first connected the injury to the prescribing or dispensing decision for the negligence route. These dates are often different. (2) Apply the right clock to each route, 3 years for the 1991 Act, 2 years for clinical negligence, plus the absolute 10-year long stop on the 1991 Act side. (3) Identify whether either route remains live. If one route is statute-barred but the other isn't, your case still survives. If you only realise after 30 months that a doctor failed to warn you, the negligence claim is statute-barred but a 1991 Act claim against the manufacturer may still be live.

Imagine a child exposed to a drug in utero who develops symptoms at age 8. The 10-year long stop may have already run on the 1991 Act route. The negligence route remains open until the child's 20th birthday. Two clocks. Different rules. Always check both.

↑ Back to top

The six statutory defences manufacturers use, and how plaintiffs defeat them

Section 6(1) of the Liability for Defective Products Act 1991 sets out six defences. A producer who proves any one of them escapes strict liability entirely. Each can be defeated, but only with the right evidence.

Section 6(1)(a), "I did not put the product into circulation"

How it's pleaded: The defendant argues the product never left their control or was distributed without their authorisation (theft, parallel imports outside contract).

How it's defeated: Marketing Authorisation records held by the HPRA. The CJEU ruling in O'Byrne v Sanofi Pasteur (Case C-127/04) confirmed that "putting into circulation" includes the moment a product enters the distribution chain controlled by the manufacturer or its agent. Batch tracking data is conclusive.

Section 6(1)(b), "The defect did not exist when the product was put into circulation"

How it's pleaded: Defendant argues degradation, contamination, or alteration occurred after distribution (pharmacy storage, parallel-import re-packaging, expiry-date breach).

How it's defeated: Cold-chain records, pharmacy storage logs, original blister packs, and expert evidence on the chemical stability of the active ingredient. Where the defect is intrinsic to the formulation, this defence cannot succeed.

Section 6(1)(c), "I did not produce this for sale or distribution in the course of a business"

How it's pleaded: Available to non-commercial preparers. Rare in pharmaceutical cases. Sometimes argued by hospital pharmacies preparing one-off compounded products.

How it's defeated: The CJEU ruling in Veedfald (Case C-203/99) established that even hospital pharmacy preparation of a perfusion fluid for transplantation counted as "putting into circulation" in the course of an economic activity. Hospital compounding cases follow this authority.

Section 6(1)(d), Mandatory regulatory compliance defence

How it's pleaded: Defendant argues the defect was the inevitable consequence of complying with mandatory rules issued by a public authority (typically the HPRA or EMA).

How it's defeated: The defence is narrow. Compliance with general regulatory standards (such as Marketing Authorisation conditions) is not enough. The producer must show the defect was the inevitable consequence of a specific mandatory rule. In practice, this defence rarely succeeds in pharmaceutical cases because manufacturers retain discretion within regulatory frameworks.

Section 6(1)(e), The development-risk (state-of-the-art) defence

How it's pleaded: Defendant argues the state of scientific and technical knowledge when the medicine was placed on the market was not such that the defect could have been discovered.

How it's defeated: Four-tactic playbook. (1) Prior literature search, pharmacological journals, conference proceedings, and regulatory submissions in other jurisdictions sometimes contain early warning signals the manufacturer ignored. (2) Discovery against the manufacturer under Order 31 of the Rules of the Superior Courts, internal pharmacovigilance reports, risk assessments, and clinical trial protocols often reveal what the company knew. (3) Freedom of Information requests to the HPRA and EMA for adverse drug reaction data submitted before the alleged defect was acknowledged. (4) Parallel international regulatory action, earlier FDA black-box warnings, MHRA Drug Safety Updates, or EMA referrals are admissible evidence that the state of the art was further advanced than the manufacturer claims. The CJEU's interpretation in Commission v United Kingdom (Case C-300/95) confirmed the test is the highest level of scientific knowledge accessible to producers, not the standard of any particular producer.

Section 6(1)(f), The component-manufacturer defence

How it's pleaded: Available to producers of an active ingredient or component. They argue the defect is attributable to the design of the finished product, or to instructions given by the producer of the finished product.

How it's defeated: Component producers sometimes face direct claims when the active pharmaceutical ingredient itself was defective (manufacturing impurities, incorrect concentration, undisclosed enantiomers). Where the API itself is defective, the defence does not apply. Where the issue is the finished-product formulation, the claim shifts to the marketing authorisation holder.

Practitioner observation: In the last decade of Irish defective-pharmaceutical litigation, sections 6(1)(b) and 6(1)(e) account for the overwhelming majority of pleaded defences. Manufacturers rarely run 6(1)(c), (d), or (f) in pharmaceutical cases because the facts seldom support them. Plan your discovery strategy around 6(1)(b) and 6(1)(e) at the start of every case.

↑ Back to top

Evidence: what wins a hybrid pharmaceutical claim

In short: Pharmaceutical claims turn on documentary evidence rather than testimony. The Three-Document Evidence Triad (batch number, HPRA quality defect record, independent expert pharmacological report) wins most hybrid cases. Verbal accounts of side effects rarely succeed alone.

Pharmaceutical cases turn on documentary evidence. Verbal accounts of side effects rarely carry the day on their own.

Practitioner observation: From handling pharmaceutical injury cases in Irish courts, the most common reason an otherwise valid claim never gets off the ground is the patient binned the packaging. The pharmacy's stock control or the GP's surgery may dispose of the unit within days. Without batch evidence, linking your specific dose to a specific manufacturing run becomes much harder, and the manufacturer's section 6(1)(c) "defect did not exist when put into circulation" defence becomes much easier.

The bundle that wins a hybrid claim usually includes the following.

One practitioner pattern is worth flagging. We call it the Three-Document Evidence Triad. In hybrid cases, the winning evidence bundle almost always pairs (a) the batch number, (b) an HPRA quality-defect record or recall notice, and (c) an independent expert pharmacological report. The Three-Document Evidence Triad works because each leg supplies what the others cannot: the batch number identifies the specific manufacturing run, the HPRA record supplies independent regulatory acknowledgement of a defect, and the expert report ties the defect to the injury through medical causation. Without all three, causation arguments tend to dissolve under cross-examination. With all three, even strict-liability defendants tend to settle early.

↑ Back to top

The expert witnesses needed to win a pharmaceutical case

In short: Pharmaceutical claims are document-led but expert-driven. Twelve categories of expert witness commonly appear in Irish pharmaceutical litigation, ranging from pharmacologists and toxicologists to actuaries and care-needs assessors. The right expert mix is case-specific and is often what separates a winning claim from a losing one.

Pharmaceutical claims are document-led but expert-driven. The categories of expert evidence below are typically required to prove a hybrid claim.

Not every case needs every expert. A typical hybrid pharmaceutical case involves 4-6 expert categories at trial. Catastrophic injury cases routinely involve 8-10. The cost of expert evidence is the single largest expense in a pharmaceutical claim and is usually recoverable from the defendant if the claim succeeds. For more on expert evidence procedure, see our cluster page on independent expert reports.

↑ Back to top

The complete evidence catalogue: every document worth seeking

In short: Pharmaceutical claims rest on documentary evidence drawn from 18 distinct sources, ranging from HPRA records and EMA pharmacovigilance data to State Claims Agency NIMS reports and the patient's own clinical history. The catalogue below lists each source, what it proves, and how to obtain it.

Pharmaceutical claims rest on documentary evidence. The catalogue below sets out every documentary source potentially useful in a hybrid claim, where to obtain it, and what it proves.

↑ Back to top

The pharmacovigilance system: how the regulator produces the evidence claimants need

In short: Pharmacovigilance is the science and practice of detecting, assessing, and preventing adverse drug reactions. The Irish system runs on Yellow Card reports, HPRA review, EMA EudraVigilance referrals, PRAC assessment, and Direct Healthcare Professional Communications. Each step in the chain produces evidence that can be obtained for civil litigation.

Pharmacovigilance is the science and practice of detecting, assessing, and preventing adverse effects of medicines once they are on the market. Ireland's pharmacovigilance system is operated by the HPRA in coordination with the EMA. Understanding the system helps claimants identify what evidence exists and how to access it.

Marketing Authorisation Holder duties

The Marketing Authorisation Holder (MAH) for a medicine has continuing legal duties to monitor the safety of its product, report adverse drug reactions, conduct Periodic Safety Update Reports, maintain a Risk Management Plan, and update the SmPC and PIL when new risks emerge. Failure to comply is a regulatory offence and is admissible evidence in civil proceedings.

The Yellow Card scheme

The Yellow Card scheme (operated by the HPRA) collects spontaneous reports of suspected adverse drug reactions from patients, carers, and healthcare professionals. Reports build a population-level picture. Where a signal emerges, the HPRA may issue a safety notice, request the MAH to update the SmPC, or refer the medicine for EMA review.

Black-triangle medicines (additional monitoring)

Medicines marked with an inverted black triangle (▼) on the PIL are subject to additional monitoring. The status flags new medicines and medicines for which more safety data is being actively gathered. The black-triangle list changes over time as the EMA Pharmacovigilance Risk Assessment Committee (PRAC) reviews accumulated data.

Direct Healthcare Professional Communications (DHPCs)

Where new safety information requires urgent action by prescribers, the MAH (with regulatory approval) issues a DHPC. The communication is sent to all relevant prescribers in the country. DHPCs are important evidence in failure-to-warn claims because they document the date the manufacturer acknowledged a risk and the date prescribers were formally told.

Article 31 referrals

Where a serious safety concern arises about a medicine across the EU, the European Commission, a Member State, or the MAH can refer the medicine to the EMA under Article 31 of Directive 2001/83/EC. PRAC reviews the medicine and issues recommendations. Article 31 referrals (such as the 2018 fluoroquinolone review) generate substantial public regulatory documentation that is admissible evidence.

↑ Back to top

Interactive tools: decision tree, time-limit calculator, first-7-days checklist

In short: Three on-page tools help you assess your position before instructing a solicitor: a decision tree for claim eligibility, a time-limit calculator covering both the 3-year and 2-year clocks, and a 7-day evidence checklist. None replace specialist advice, but each surfaces the questions a solicitor will ask at the first meeting.

Three on-page tools help you assess your position before instructing a solicitor. None replaces specific legal advice. Each is designed to give you the framing questions a solicitor would ask in a first consultation.

↑ Back to top

Irish case law: the rulings that govern hybrid pharmaceutical claims

In short: Irish High Court and Supreme Court jurisprudence shapes the negligence side of every hybrid pharmaceutical claim. The Dunne standard of care (1989), the Geoghegan test for informed consent (2000), and the Morrissey decision on systemic failures (2020) are the three pillars on which Irish clinical negligence law currently rests.

Irish High Court and Supreme Court jurisprudence shapes the negligence side of every hybrid pharmaceutical claim. The cases below establish the standard of care, the test for informed consent, and the procedural posture courts adopt in pharmaceutical contexts.

↑ Back to top

CJEU case law directly binding Irish courts on the 1991 Act

The Liability for Defective Products Act 1991 transposes Council Directive 85/374/EEC. The Court of Justice of the European Union has jurisdiction to interpret that directive, and its rulings bind Irish courts under Article 267 TFEU. The seven rulings below shape every defective-pharmaceutical claim in Ireland.

↑ Back to top

Pandemrix narcolepsy: how Ireland's vaccine claims actually settled

In short: Pandemrix is the Irish name for the swine-flu vaccine GlaxoSmithKline supplied during the 2009-2011 H1N1 pandemic. Roughly 100 Irish children and young adults developed narcolepsy and cataplexy after vaccination. Aoife Bennett's landmark High Court action settled in November 2019 after a five-week hearing. Benjamin Blackwell's settlement in November 2020 set a 50% benchmark that resolved approximately 80 outstanding cases.

Between October 2009 and March 2011, Ireland ran a mass swine-flu vaccination programme using Pandemrix, a vaccine manufactured by GlaxoSmithKline (GSK). Around 75 to 100 Irish children and young adults developed narcolepsy after receiving the vaccine, often with cataplexy. European data later showed a 12 to 14-fold increased risk in those with a specific HLA-DQB1*0602 gene variant.

What Pandemrix shows about Irish pharmaceutical litigation: the cases ran on a hybrid basis, combining strict-liability theory under the 1991 Act with negligence-based claims for failure to warn against the State and HSE. The State indemnity meant the State Claims Agency carried the financial risk. Plaintiffs reported the process as adversarial and protracted. As of 2025, the Department of Health was working on a proposed dedicated State Vaccine Injury Compensation Scheme, with parliamentary debate covering balance-of-probabilities standards, presumptive injury tables, and retroactive coverage per gov.ie updates [9]. The scheme was not yet enacted at the time of writing.

Sodium valproate (Epilim) and Foetal Valproate Spectrum Disorder

Sodium valproate, sold in Ireland as Epilim and manufactured by Sanofi, is an effective anti-epilepsy and bipolar medicine. Taken in pregnancy, it carries severe teratogenic risk. Around 30 to 40 percent of in-utero exposures result in neurodevelopmental disability including autism spectrum disorder. Around 10 percent result in major physical malformations such as spina bifida or cleft palate. The collective diagnosis is Foetal Valproate Spectrum Disorder (FVSD).

The HSE 2018 review estimated that around 1,250 Irish children have been affected by valproate exposure since the drug was licensed in 1975. A 2021 Noteworthy investigation put the figure as high as 3,000.

Specialist firms have called for a dedicated redress scheme to avoid what one solicitor described as "perpetual litigation".

On 22 July 2025, Health Minister Jennifer Carroll MacNeill formally commenced the non-statutory Sodium Valproate Inquiry chaired by Bríd O'Flaherty BL. The Inquiry runs in three strands: a review of the historical timeline of valproate use and safety information, oral statements from those affected and their families (held in private), and an assessment of current safety systems for anti-seizure medications in women of childbearing potential per Department of Health publications [9]. The Inquiry is scheduled to last 12 to 18 months. Affected families should know that the Inquiry is fact-finding and recommendation-making. It is not itself a compensation scheme. Participating in the Inquiry does not preclude a separate compensation claim, and a separate compensation claim is still required to recover damages.

Children's claims have a longer limitation runway because the standard 2-year clock does not start running until the child's 18th birthday. Claims for children need careful navigation, especially where the 1991 Act's 10-year long stop has run.

Other pharmaceutical safety signals with Irish litigation interest

Pandemrix and sodium valproate are Ireland's two highest-profile pharmaceutical injury litigations. Other medicines have generated safety concerns, regulatory action, and emerging litigation interest in 2024-2026. The dossiers below are short factual summaries. None constitutes legal advice on any specific case.

The dossiers above are factual summaries of regulatory action and pharmacovigilance signals. The existence of a regulatory restriction or a published adverse-effect profile does not, on its own, establish a viable claim. Each case turns on the specific medicine, the specific facts of prescribing and dispensing, and the specific injury suffered. The Hybrid Claim Test should be applied to every fact pattern.

↑ Back to top

The 9 December 2026 cutover: 1991 Act vs Directive (EU) 2024/2853

In short: On 9 December 2026, Ireland must transpose Directive (EU) 2024/2853 into national law. The new Directive applies to medicines placed on the market on or after that date. Pre-existing medicines remain governed by the 1991 Act. The cutover introduces rebuttable presumptions of defectiveness, a 25-year long stop for latent injuries, mandatory disclosure obligations, and an expanded scope covering software and AI.

Ireland must transpose Directive (EU) 2024/2853 [2] into national law by 9 December 2026. The Department of Enterprise has confirmed it expects to meet the deadline. The new regime will not retroactively affect medicines placed on the market before that date. The 1991 Act continues to govern pre-cutover products.

The practical takeaway: how do you know which regime applies to your medicine? Check the marketing authorisation date for the specific product and pack you received. The HPRA "Find a Medicine" tool gives the regulatory history. Most medicines in current circulation will fall under the 1991 Act for years to come. The new directive matters most for innovative drugs, biosimilars, and digital therapeutics launched in late 2026 and beyond.

Article 10's rebuttable presumption of defectiveness is the headline change for plaintiffs. Take a complex case where the chain of causation requires expert toxicology evidence. The court will be empowered to presume defect or causation if the claimant can show the case is excessively difficult to prove on the standard burden. The producer must then disprove. Several Irish commentators expect this provision to drive more early settlements.

↑ Back to top

Do you need IRB authorisation?

In short: The Injuries Resolution Board (formerly PIAB) is a statutory body that screens most personal-injury claims in Ireland. Pharmaceutical claims framed as pure product liability under the 1991 Act may need IRB authorisation. Claims framed as clinical negligence are exempt under section 3(d) of the PIAB Act 2003. Hybrid claims usually proceed directly to the High Court because the negligence element controls the procedural route.

This question trips most claimants. The short answer depends on how the claim is framed.

All personal injury claims in Ireland [11] go through the Injuries Resolution Board first, with one statutory exception: medical negligence claims under section 3(d) of the Personal Injuries Assessment Board Act 2003. The exemption was created because clinical-causation cases involve evidence the IRB's streamlined process is not designed to handle.

A pure 1991 Act claim against a drug manufacturer is technically a personal injury claim that falls outside the medical-negligence exemption. IRB authorisation may be required before High Court proceedings can issue. A claim framed as clinical negligence against a prescriber or pharmacist falls inside the exemption and proceeds directly to the High Court. A hybrid claim usually proceeds directly because the negligence element controls the procedural route.

This nuance is missed by most solicitor pages. It matters because filing an IRB application unnecessarily can waste 9 months and incur costs. Filing High Court proceedings without authorisation in a case that needed it can be fatal. Get the framing right at the start with a solicitor experienced in both routes.

The full litigation pathway from injury to judgment

In short: Pharmaceutical claims that proceed beyond pre-action correspondence follow a 13-step procedural pathway through the High Court Clinical Negligence List. Typical resolution takes 2 to 5 years from issue of summons. Most claims settle. Trial is comparatively rare. Practice Directions HC131 and HC132, effective 28 April 2025, compress timelines through mandatory pre-trial requirements.

Pharmaceutical claims that proceed beyond pre-action correspondence follow a defined procedural pathway through the High Court Clinical Negligence List or the Personal Injuries List. The steps below set out the typical sequence with rough timing, recognising that timelines vary case by case.

Most pharmaceutical claims settle. Trial is comparatively rare. The procedural framework above sets the stage for negotiation: each step generates evidence, narrows issues, and changes the parties' assessment of trial risk. A claim properly built through steps 1-9 frequently settles between steps 10 and 12.

↑ Back to top

Multi-party action procedures: how Ireland handles claims involving many people

In short: A multi-party action is Ireland's nearest equivalent to a class action. Where a defective medicine harms many patients in similar ways, Ireland uses test cases, lead actions, and judicial case management to resolve groups of claims efficiently. The Pandemrix and sodium valproate litigations are the two largest examples. The Representative Actions Act 2023 introduced a new EU-derived collective redress mechanism for certain consumer claims.

Where a defective medicine harms many patients in similar ways, Ireland uses test-case strategy and Order 18A of the Rules of the Superior Courts to coordinate. Ireland does not have a true class-action regime in the US sense, but has functional equivalents that have run successfully.

Test-case strategy as used in Pandemrix

Pandemrix narcolepsy litigation followed a test-case model. Bennett ran first, settled at full value. Blackwell ran second, set the 50% benchmark. Approximately 80 outstanding cases then settled within the framework Blackwell established. The State Claims Agency consented to the framework approach. This approach works where: (a) the underlying scientific causation question is common, (b) injury severity varies but can be banded, and (c) the defendant is institutionally willing to standardise.

Order 18A representative actions

Order 18A of the RSC permits one or more persons to defend or prosecute proceedings on behalf of all persons with the same interest. It is a procedural device, not a substantive class regime. Its use in pharmaceutical cases is limited because individual causation and damage typically differ between claimants.

The Representative Actions Act 2023 and Qualified Entities

The Representative Actions for the Protection of the Collective Interests of Consumers Act 2023 [17] commenced on 30 April 2024. It transposes Directive (EU) 2020/1828 on representative actions for the protection of collective consumer interests. Designated Qualified Entities can bring representative actions in the High Court for injunctive relief or redress. Consumers must opt in. The framework applies to life-sciences and pharmaceutical claims.

A practical limitation has emerged. Ireland's prohibition on third-party litigation funding (rooted in the rules against champerty and maintenance) constrains Qualified Entities, who tend to be non-profits without litigation capital. Some Qualified Entities have lodged complaints with the European Commission arguing this funding constraint breaches the spirit of the Directive. The position may evolve.

↑ Back to top

Patient Safety Act 2023: mandatory open disclosure

The Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023 [12] commenced on 26 September 2024. Schedule 1 includes specified medication-related serious incidents. Where one of those incidents occurs, the healthcare provider must disclose it to the patient and notify the relevant regulator (HIQA, Chief Inspector, or Mental Health Commission) within seven days through the National Incident Management System.

For your claim, two provisions matter. Section 10 of the Act states that information and apologies given during a notifiable-incident disclosure meeting are not admissible as an admission of liability. The disclosure cannot itself prove your case. But the disclosure may help you understand what happened, identify the right defendants, and clarify the date of knowledge for limitation purposes.

Section 77 makes it a criminal offence for a provider to fail to comply with the open-disclosure requirement without reasonable excuse. This shifts the cultural picture even where the disclosure itself is inadmissible.

Causation in pharmaceutical claims: how Irish courts decide it

In short: Causation is usually the hardest part of a defective drug claim. The claimant must prove on the balance of probabilities that the medicine caused the injury, not merely that it could have. Where multiple causes contributed, the Bonnington Castings material contribution test applies. Establishing the causal link requires expert pharmacological evidence drawn from a consultant practising in the same specialty as the prescriber.

Causation is usually the hardest part of a defective drug claim. Establishing that a medicine caused an injury requires more than temporal proximity. Irish courts apply established causation tests, with refinements from CJEU jurisprudence specific to pharmaceutical evidence.

The "but-for" test (the default)

The claimant must show, on the balance of probabilities, that the injury would not have occurred but for the defect. This is the default test for personal injury actions in Ireland and the starting point for any pharmaceutical claim. Where the injury has only one plausible cause, but-for causation is straightforward.

Material contribution to damage

Where multiple causes (including the defective medicine) contributed to the same indivisible injury, Irish courts apply the principle from Bonnington Castings v Wardlaw [1956] AC 613. The claimant need only show the defect made a material contribution to the damage. The Bonnington principle has been applied in Irish industrial-disease cases and translates directly to pharmaceutical cases involving multifactorial injuries (organ damage with comorbidity, neurodevelopmental delay with multiple contributors).

Material contribution to risk of damage

The McGhee v National Coal Board [1973] 1 WLR 1 principle (material contribution to risk where direct causation is unprovable due to scientific uncertainty) is more contested in Ireland. The Irish courts have applied it cautiously and have not generally extended it beyond the asbestos-mesothelioma context where Fairchild v Glenhaven [2003] 1 AC 32 was decided. In pharmaceutical cases, plaintiffs argue for it in cluster injuries (such as Pandemrix narcolepsy) where the population-level signal is strong but individual causation is hard.

The N.W. v Sanofi Pasteur "serious, specific and consistent" evidence test

The CJEU's ruling in N.W. v Sanofi Pasteur (Case C-621/15) is directly binding on Irish courts in cases under the 1991 Act. The court held that, in the absence of medical research either confirming or excluding a causal link, claimants can prove defectiveness and causation through "serious, specific and consistent" circumstantial evidence: temporal proximity to vaccination, prior good health, family history, and absence of competing causes. This ruling materially lowers the proof bar for pharmaceutical claims where the science is unsettled.

Pre-existing conditions and the "eggshell skull" rule

If the claimant had a pre-existing condition that made them more susceptible to harm from the medicine, the defendant takes the claimant as they find them. The defendant cannot reduce damages because an ordinary patient would have suffered less. The eggshell-skull rule applies fully to pharmaceutical cases.

Apportionment between defendants in hybrid claims

Section 34 of the Civil Liability Act 1961 [13] governs apportionment between concurrent wrongdoers. In a hybrid claim where both the manufacturer and a prescriber contributed to the injury, the court apportions liability based on degrees of fault. Joint and several liability means the claimant can recover the full sum from either defendant, leaving the defendants to argue contribution between themselves under section 21.

For deeper coverage of causation principles in clinical contexts, see our cluster page on causation.

↑ Back to top

The Learned Intermediary Doctrine: why warnings go to your doctor, not to you

In Irish and EU pharmaceutical law, the manufacturer's duty to warn about prescription-medicine risks runs to the prescribing doctor, not directly to the patient. This is the Learned Intermediary Doctrine. The doctor is treated as a sophisticated professional who weighs the risks and translates them into individualised advice for each patient.

The doctrine has three practical consequences for claims.

(1) The Summary of Product Characteristics (SmPC) is the central warning document, not the patient information leaflet (PIL). The SmPC is written for prescribers. The PIL is a regulated patient summary. A failure-to-warn claim normally focuses on whether the SmPC adequately conveyed the risk to a prescribing doctor of ordinary competence at the relevant time. Comparing the SmPC in force when the medicine was prescribed against the SmPC in force when the alleged defect became known often reveals the case.

(2) The prescriber's reading of the SmPC matters. If the manufacturer warned the prescriber adequately and the prescriber failed to communicate the risk to the patient, the manufacturer is usually off the hook on the warning point. The case shifts to clinical negligence against the prescriber. This is one of the most common ways a pure 1991 Act claim becomes a hybrid claim, or vice versa.

(3) The doctrine has limits. Direct-to-consumer products (over-the-counter medicines, vaccines administered en masse outside individualised consultation, online-prescribed medicines via algorithm-only intake) test the doctrine. Where there is no genuine learned intermediary in the chain, courts are more willing to impose direct duty-to-warn obligations on manufacturers. Mass vaccination programmes such as Pandemrix sat at this boundary. The plaintiffs argued that consenting forms presented at large vaccination clinics did not amount to genuine learned-intermediary mediation.

The doctrine is implicitly recognised in the European pharmaceutical regulatory framework. Article 59 of Directive 2001/83/EC requires distinct labelling and PIL content. The differentiation is explicit acknowledgement that prescribers and patients receive different information, and that the prescriber is the primary recipient of safety-critical detail.

↑ Back to top

How Irish courts value a defective drug injury: damages in detail

Damages in Irish defective pharmaceutical claims fall into general damages and special damages, with additional categories for catastrophic cases. The framework below sets out the heads of recovery and how each is calculated.

General damages under the Personal Injuries Guidelines 2021

General damages compensate for pain, suffering, and loss of amenity. Since 24 April 2021, awards have been assessed under the Judicial Council Personal Injuries Guidelines 2021 [18], which replaced the Book of Quantum. Pharmaceutical injuries can fall into multiple Guidelines categories at once. The court picks the dominant injury, calibrates within bracket, then uplifts to reflect the compounding effect of secondary injuries.

Every figure cited in the Personal Injuries Guidelines is indicative, not a fixed entitlement. The eventual award depends on medical evidence, expert testimony, contributory factors, and the specific injury category. A solicitor experienced in pharmaceutical cases can give a calibrated range early in the case.

The Guidelines state indicative ranges, but in practice, severe pharmaceutical injuries with multi-system involvement usually attract the higher end of the relevant bracket plus a substantial adjustment for overlap across categories. The Guidelines invite that adjustment in their introductory text. The court doesn't add the brackets together. It picks the dominant injury, calibrates within bracket, then uplifts to reflect the compounding effect of the secondary injuries. This is why pharmaceutical cases with severe psychiatric overlay, organ damage, and reproductive consequences settle higher than the dominant-injury bracket would suggest in isolation.

Special damages: financial losses and ongoing costs

Special damages are the financial losses caused by the injury. Each head must be vouched (proved by documentary evidence). The principal heads are:

• Past medical expenses, medical bills, prescription costs, physiotherapy, counselling, paid up to the date of trial or settlement
• Future medical expenses, anticipated ongoing treatment, calculated using medical-evidence-based forecasts
• Past lost earnings, proved by Revenue records, payslips, and employer letters
• Future lost earnings, calculated using a multiplier and multiplicand approach or actuarial evidence, depending on case complexity
• Aids and appliances, wheelchairs, prosthetics, mobility equipment, communication devices
• Care costs, commercial care from agencies, or gratuitous care provided by family members compensated at the carer's notional commercial rate
• Travel costs, to medical appointments and rehabilitation
• Accommodation modification, home adaptation for disability, sometimes including the cost of moving to a more suitable property

For more on future care costs in catastrophic cases, see future care costs.

Other damages categories

Aggravated damages may be awarded where the defendant's conduct was particularly egregious, concealment of known risks, deliberate suppression of safety data, or aggressive defence tactics designed to wear out the claimant. They are awarded to compensate the claimant for additional injury, not to punish the defendant.

Exemplary damages are rare in Ireland but theoretically available where the conduct is so outrageous that compensatory damages alone are inadequate. The test in Conway v Irish National Teachers' Organisation [1991] is demanding. They are not commonly awarded in pharmaceutical cases.

Bereavement damages for the death of a family member through pharmaceutical injury are governed by section 49 of the Civil Liability Act 1961 [13]. The cap is currently €35,000, divided among the statutory dependants. Funeral expenses are recoverable separately.

Periodic Payment Order vs lump sum

The Civil Liability (Amendment) Act 2017 [19] gives Irish courts power to make Periodic Payment Orders (PPOs) for catastrophic injury cases. A PPO funds annual index-linked payments for life, rather than a single lump sum. PPOs are increasingly common in pharmaceutical injury cases involving lifelong care needs.

The choice between PPO and lump sum is one of the most consequential decisions in a catastrophic-injury case. It should be discussed with a solicitor experienced in pharmaceutical cases, an actuary, and (if appropriate) a financial adviser before any settlement is finalised.

Tax treatment of pharmaceutical injury settlements

Personal injury awards are tax-free in Ireland under section 189A of the Taxes Consolidation Act 1997. Income generated from invested settlement funds is generally taxable. PPO payments are tax-free under section 189B.

Catastrophic injury settlements often interact with means-tested benefits. The Disability Allowance and other welfare benefits have means thresholds that a settlement can exceed. Special-needs trusts and similar structures can preserve benefit entitlement while protecting the settlement. Tax and benefits planning should be done at the time of settlement, not afterwards.

↑ Back to top

Special categories: children, incapacitated adults, fatal cases

Three categories of pharmaceutical injury claim follow modified procedural and substantive rules.

Children's pharmaceutical injury claims

Limitation runs differently for children. The 2-year clinical-negligence clock under section 3 of the Statute of Limitations (Amendment) Act 1991 does not start running until the child's 18th birthday (per section 5 of that Act). The 1991 Act 10-year long stop in section 7(2) is absolute and runs from the producer's circulation date regardless of the child's age. This is why valproate cases involving older exposures often run on the negligence route while the product-liability route has expired.

Children's settlements require court approval. Order 22 of the Rules of the Superior Courts governs the procedure. The court reviews the proposed settlement to ensure it is in the child's best interests. The court can require the settlement to be invested for the child's benefit until majority. PPOs are particularly common in children's catastrophic-injury cases because they provide lifelong support without exposing the family to investment risk. For more, see our cluster page on claims for children.

Incapacitated adult claims

Adults who lack decision-making capacity at the time of injury or settlement are protected by the framework of the Assisted Decision-Making (Capacity) Act 2015 [20], which commenced on 26 April 2023 and replaced the historic Wards of Court regime. The Decision Support Service oversees decision-making representatives. Settlements of pharmaceutical injury claims for adults lacking capacity require court approval and may require a court-appointed representative.

Limitation is also tolled for adults who lack capacity. The 2-year clinical-negligence clock and the 3-year 1991 Act clock do not run during incapacity. The 10-year long stop on the 1991 Act remains absolute.

Fatal pharmaceutical injury claims

Where a defective medicine causes death, two categories of claim arise under sections 47-49 of the Civil Liability Act 1961.

The estate's claim, brought by the personal representative under section 7. The estate can claim for losses suffered by the deceased before death (medical expenses, pain and suffering, loss of earnings between injury and death). The 2-year limitation runs from the date of death, not the date of knowledge.

The dependants' claim, brought by the personal representative on behalf of statutory dependants (spouse, civil partner, children, parents). Dependants can claim for loss of services, loss of dependency on the deceased's earnings, and statutory bereavement damages capped at €35,000 (divided among the dependants). Funeral expenses are recoverable separately.

Fatal pharmaceutical injury cases also engage the Coroner's jurisdiction. The Coroner's inquest establishes the cause of death and may produce verdicts, recommendations, or findings of fact that are admissible (in limited circumstances) in the civil action. For more on death claims, see our cluster page on claim after death.

↑ Back to top

Alternative causes of action when the 1991 Act runs out

Where the 1991 Act 10-year long stop has run, or the producer cannot be identified, three alternative causes of action may still be available. None replaces the 1991 Act, but they sometimes preserve a claim that would otherwise be lost.

Sale of Goods and Supply of Services Act 1980

The Sale of Goods and Supply of Services Act 1980 [21] implies terms about merchantable quality and fitness for purpose into consumer sales. A pharmacy that supplied a defective medicine may be liable in contract to the patient who paid for it (or to the State for State-funded prescriptions). Limitation runs for six years from the breach of contract under section 11(1) of the Statute of Limitations 1957.

Common law negligent misstatement

The Hedley Byrne v Heller principle imposes liability for negligent misstatement where a defendant assumes responsibility for advice or information on which the claimant reasonably relies. In pharmaceutical contexts, this can apply to misleading marketing, off-label promotion claims, or inadequate patient information leaflets.

Consumer Protection Act 2007

The Consumer Protection Act 2007 [22] prohibits misleading commercial practices and unfair commercial practices. Off-label promotion of pharmaceutical products to consumers, where the indication has not been approved, may constitute a misleading practice. The Act provides civil remedies including damages.

↑ Back to top

The regulators: HPRA, EMA, PSI, Medical Council, HIQA

Five regulatory bodies sit behind every pharmaceutical injury claim in Ireland. Understanding their roles helps claimants identify evidence, assess concurrent complaint paths, and navigate professional conduct procedures.

Health Products Regulatory Authority (HPRA)

The HPRA is the statutory regulator for human and veterinary medicines in Ireland. Its statutory basis is the Health Products Regulatory Authority Act 2014. The HPRA grants Marketing Authorisations, monitors post-market safety, classifies and coordinates recalls (Class I, II, III), issues Direct Healthcare Professional Communications, operates the Yellow Card adverse drug reaction reporting scheme, and enforces the Falsified Medicines Directive. HPRA documentation is the central regulatory evidence in defective-pharmaceutical claims.

European Medicines Agency (EMA)

The EMA coordinates pharmaceutical regulation across the EU. Authorisation procedures include the Centralised Procedure (mandatory for biotech and orphan products), the Decentralised Procedure, and the Mutual Recognition Procedure. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviews safety signals and coordinates Article 31 referrals. EMA documentation, including European Public Assessment Reports (EPARs) and PRAC recommendations, is admissible evidence in Irish courts.

Pharmaceutical Society of Ireland (PSI)

The PSI regulates pharmacy practice in Ireland under the Pharmacy Act 2007. Pharmacists must register with the PSI. Complaints about pharmacy errors (LASA confusion, wrong-dose dispensing, failure to counsel under Regulation 10 of S.I. 488/2008) are investigated by the PSI Professional Conduct Committee. A PSI complaint can run in parallel with a civil claim. PSI findings of professional misconduct are admissible evidence in civil proceedings.

Medical Council

The Medical Council regulates medical practitioners in Ireland under the Medical Practitioners Act 2007. Doctors must register with the Council. Complaints about prescribing errors, failure to warn, or off-label prescribing without informed consent are investigated by the Council's Fitness to Practise procedures. Council findings can run in parallel with civil claims.

Health Information and Quality Authority (HIQA)

HIQA is the inspector and regulator of healthcare services in Ireland. Under the Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023, certain pharmaceutical-related serious incidents must be notified to HIQA, the Mental Health Commission, or the Chief Inspector of Social Services within seven days. Notifications are made through NIMS. Notification records are admissible evidence in civil proceedings, accessible by Data Protection request.

↑ Back to top

Practical decision points: settle or litigate, costs, confidentiality

Three decision points come up in nearly every pharmaceutical injury case. Each affects outcome and cost.

Settle or litigate

Most pharmaceutical claims settle. Trial is comparatively rare. Settlement gives certainty and speeds up payment. Litigation produces public judgment and (sometimes) higher awards but carries trial risk. The decision depends on the strength of the evidence, the quality of the defence, the defendant's appetite to pay, and the claimant's tolerance for delay. Children's settlements always require court approval. Settlements of incapacitated-adult claims under the Assisted Decision-Making (Capacity) Act 2015 require court approval in most cases.

Confidentiality clauses

Defendants frequently propose confidentiality clauses as a settlement condition. The clauses limit what the claimant can say publicly about the case. They are legally enforceable in Ireland but subject to public policy limits. A clause that prevented the claimant from making protected disclosures under the Protected Disclosures Acts 2014 and 2022, or from cooperating with regulatory investigations, would be unenforceable. A clause that required the claimant to suppress evidence of ongoing patient safety risks would be against public policy.

The trade-off matters. Confidentiality clauses can produce higher settlement values but limit the claimant's contribution to public awareness of pharmaceutical safety issues. Some claimants in Pandemrix and valproate cases declined confidentiality and accepted lower settlement values to preserve the right to speak publicly.

Costs reality

Costs in pharmaceutical injury cases are substantial. Expert evidence alone routinely runs to mid-five figures. Discovery in complex cases can require external review of tens of thousands of documents. Section 169 of the Legal Services Regulation Act 2015 establishes that costs follow the event, but the court has discretion to depart from that rule.

Specialist firms typically work on a no-win-no-fee* basis for pharmaceutical injury cases that pass an internal merits review. Disbursements (expert fees, court fees, counsel fees) are usually advanced by the firm and recovered from the defendant if the claim succeeds. Read more on no-win-no-fee* arrangements.

If the claim fails and a costs order is made against the claimant, the claimant could face the defendant's costs. After-the-event (ATE) insurance is one mitigation but is not always available for pharmaceutical cases. The decision to issue proceedings should be made with full understanding of cost exposure.

↑ Back to top

Common mistakes that defeat defective drug claims

Five mistakes recur across pharmaceutical cases that don't get off the ground.

1. Returning the medicine before photographing it. The pharmacy's stock control or the GP's surgery may dispose of the unit. Without batch evidence, linking your specific unit to a specific manufacturing run becomes much harder.

2. Missing the date-of-knowledge analysis. Many claimants assume the 3-year clock starts the day they took the drug. For latent injuries (organ damage, autoimmune disease, certain cancers, in-utero teratogenicity), the date of knowledge can be years later. The clock starts when you reasonably could have linked the injury to the drug. Don't assume you're out of time without legal advice.

3. Ignoring the 10-year long stop in vaccine and old-drug cases. The 10-year rule under section 7(2) of the 1991 Act is absolute. It overrides minority and incapacity protections. A vaccine administered 12 years ago is normally outside the Act, although a clinical-negligence claim against the prescriber may still be live.

4. Confusing the inquiry with a claim. The Sodium Valproate Inquiry is fact-finding. Cervical Check Inquiries are fact-finding. They make recommendations. They do not award compensation. A separate civil action is required to recover damages.

5. Filing IRB applications when not required, or missing them when required. Get the framing right at the start.

↑ Back to top

Emerging issues: AI prescribing, digital therapeutics, personalised medicine, Brexit, counterfeit sales

Five forward-looking issues are reshaping defective pharmaceutical claims in Ireland. Each will become more prominent in 2026 and beyond.

AI in prescribing

The EU AI Act (Regulation (EU) 2024/1689) classifies clinical decision-support systems as high-risk AI. Where an AI prescribing tool produces a recommendation that the prescriber adopts, liability allocation between clinician, hospital, and AI vendor becomes complex. The new 2024 Product Liability Directive expands "product" to include AI systems and software. The first generation of cases will test how Irish courts apportion responsibility when an AI tool contributed to a prescribing error.

Digital therapeutics

Software prescribed by doctors as a treatment in its own right (smartphone apps for insomnia, depression, addiction) is a recognised regulatory category. The 2024 Directive treats these as products. Failure of the software, inadequate warnings about contraindications, or algorithmic error producing harmful recommendations are foreseeable claim categories.

Personalised medicine and pharmacogenomics

Pharmacogenomic testing identifies genetic variants that affect drug metabolism. CYP450 polymorphisms, HLA-B*5701 testing for abacavir, and DPD deficiency testing for fluorouracil are examples of established standards of care. As genetic testing becomes routine, the standard of care evolves. Failure to test for known polymorphisms before prescribing a medicine with known genotype-dependent toxicity may, in time, become actionable as clinical negligence.

Brexit and the Northern Ireland Protocol

Many medicines sold in Ireland are manufactured by UK-based or UK-headquartered companies. Post-Brexit, service of proceedings on UK defendants is governed by the EU-UK Trade and Cooperation Agreement and bilateral conventions, not the Brussels Recast Regulation. Recognition of Irish judgments in the UK is also more complex. The Northern Ireland Protocol maintains EU pharmaceutical regulation in Northern Ireland. Cross-border supply chains create jurisdictional questions that did not exist before 2021.

Counterfeit medicines and online sales

The HPRA detained 763,027 dosage units of falsified or illegal medicines in 2025. Counterfeit GLP-1 agonists, anabolic steroids, and erectile dysfunction medicines purchased online accounted for a significant share. The Falsified Medicines Directive (2011/62/EU), transposed into Irish law, requires safety features on most prescription medicines and authentication at the point of dispensing.

Counterfeit-medicine cases rarely produce viable claims. The "phantom manufacturer" problem means the producer cannot be identified. The 1991 Act requires the producer or importer to be identifiable. A patient injured by a counterfeit GLP-1 product purchased through an unregulated online seller usually has no defendant within the Irish legal system. The most effective preventative is purchasing only from PSI-registered Irish pharmacies.

↑ Back to top

Frequently Asked Questions

Common questions and answers in plain English.

What to consider next

If you've worked through this guide, three follow-up questions usually come up. Each links to a more detailed cluster page on the topic.

Glossary: pharmaceutical injury law terms in plain English

Each definition under 40 words. Terms in the order they typically arise in a case.

Marketing Authorisation (MA)

The licence granted by the HPRA or EMA permitting a medicine to be placed on the market in Ireland. Without an MA, supply is unlawful.

Marketing Authorisation Holder (MAH)

The legal entity that owns the Marketing Authorisation. The MAH carries the primary regulatory and pharmacovigilance duties for the medicine.

Summary of Product Characteristics (SmPC)

The regulatory document setting out the indications, dosage, contraindications, and recognised adverse effects of a medicine. The central warning document for prescribers.

Patient Information Leaflet (PIL)

The patient-facing summary included in the dispensing pack. Translates the SmPC into accessible language. Subject to readability standards.

Direct Healthcare Professional Communication (DHPC)

An urgent safety communication from the MAH to all prescribers in the country, with regulatory approval, when new safety information requires immediate action.

Periodic Safety Update Report (PSUR)

A regular safety review submitted by the MAH to regulators, summarising adverse drug reactions and emerging signals over a defined period.

Suspected Unexpected Serious Adverse Reaction (SUSAR)

A serious adverse drug reaction not described in the SmPC. SUSARs trigger expedited regulatory reporting and pharmacovigilance review.

Yellow Card scheme

The HPRA's spontaneous adverse drug reaction reporting system. Patients, carers, and healthcare professionals can submit reports.

Black-triangle medicine

A medicine subject to additional monitoring. Marked with an inverted black triangle (▼) on the PIL. Indicates active surveillance of safety data.

Pharmacovigilance

The science and practice of detecting, assessing, and preventing adverse effects of medicines in clinical use.

Article 31 referral

A formal referral of a medicine to the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) under Article 31 of Directive 2001/83/EC, when serious EU-wide safety concerns arise.

Quality Defect Report (Form SUR-F0180)

The HPRA form used to report a quality defect in a medicine. Reports can come from healthcare professionals, MAHs, or patients.

Recall classes

HPRA-classified levels of medicine recall. Class I is most serious (immediate health risk). Class II is significant. Class III is minor.

Defect (under the 1991 Act)

A medicine is defective when it does not provide the safety which a person is entitled to expect, taking into account presentation, intended use, and the time it was placed on the market.

Put into circulation

A medicine is "put into circulation" when it leaves the producer's controlled distribution chain and enters the marketing process. Defines when the 10-year long stop in s.7(2) starts running.

Date of knowledge

The date the claimant became aware (or could reasonably have become aware) of the injury, the defect, and the identity of the producer. Triggers the 3-year limitation under s.7(1).

Long stop

An absolute outer limitation period. The 10-year long stop in section 7(2) of the 1991 Act extinguishes the right of action 10 years after the producer first put the product into circulation, regardless of date of knowledge.

Hybrid claim

A pharmaceutical claim combining strict liability under the 1991 Act with clinical negligence against a prescriber, dispenser, or hospital.

Learned Intermediary Doctrine

The principle that a manufacturer's duty to warn about prescription-medicine risks runs to the prescribing doctor, not directly to the patient.

Foetal Valproate Spectrum Disorder (FVSD)

A pattern of physical, neurodevelopmental, and behavioural abnormalities in children exposed to sodium valproate in utero.

Periodic Payment Order (PPO)

A court order under the Civil Liability (Amendment) Act 2017 funding annual index-linked payments for life, used in catastrophic-injury cases.

Open Disclosure

The mandatory process under the Patient Safety Act 2023 for healthcare providers to inform patients of notifiable incidents. Section 10 makes the disclosure inadmissible as an admission of liability in civil proceedings.

NIMS (National Incident Management System)

The HSE's incident reporting system, operated through the State Claims Agency. Records are accessible by Data Protection request.

Notifiable incident

A patient safety incident defined by Schedule 1 of the Patient Safety Act 2023, requiring notification to HIQA, the Mental Health Commission, or the Chief Inspector of Social Services within seven days.

Off-label prescribing

Prescribing a medicine for a condition or in a way not covered by its Marketing Authorisation. Lawful but requires informed consent and may engage Geoghegan v Harris obligations.

Falsified medicine

A medicine misrepresented as to its identity, source, or history. Distinct from a substandard or defective authorised medicine. Governed by the Falsified Medicines Directive 2011/62/EU.

↑ Back to top